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Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY, United StatesSee Articles, pages 11–15 and pages 98–103Hepar, heart, and the endothelia withinsystems, it’s been interesting that the heart is rarely mentioned. AGiven the widespread impact of hepatic disease on other organs
including the kidney, lungs, and the immune and central nervous
study in this month’s issue of the Journal of Hepatology by Maruy-
ama et al. identiﬁes a common effect of hepatitis C virus (HCV)
infection on myocardial function that is reversible following viral
eradication. Unlike the effect on other organs, however, this car-
diac connection does not reﬂect a consequence of advanced liver
disease but rather a direct result of HCV infection. A second study
by Marrone et al. explores the beneﬁt and mechanisms by which
statins, which are widely used to lower cholesterol and reduce
risk of coronary disease, improve hepatic sinusoidal cell function.
In the study by Maruyama and colleagues, extensive cardiac
evaluation was performed in 217 consecutive patients with
chronic HCV infection, including EKG, echocardiography, serum
brain-derived and atrial natriuretic peptides, and myocardial
thallium scintigraphy. Remarkably, 87% of patients with HCV
but not normal controls had abnormal thallium scans, although
no clinical manifestations of heart disease were reported. Of 92
patients who had a sustained virologic response following treat-
ment with either interferon alone or interferon plus ribavirin, all
had improved myocardial function on follow-up thallium scan,
whereas 57 patients who relapsed following either treatment
had only a transient improvement at the end of therapy, while
all patients who were non-responders (either to mono-therapy
with interferon or combined interferon–ribavirin) had no
improvement at all.
Although earlier studies have reported that HCV infection
may affect myocardial function and can be present in the tissue
[1–3], this report is remarkable by demonstrating improvement
in cardiac function following SVR, implicating the presence of
virus in causing the abnormalities. Still, lots of questions
remain. Are the ﬁndings in heart unique to HCV or are they a
common, albeit rarely sought, consequence of any systemic viral
infection? Since no myocardial biopsies were obtained, theJournal of Hepatology 20
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E-mail address: scott.friedman@mssm.edu.authors could not link the ﬁndings to the presence of HCV in
heart tissue, but even if HCV was detected, this would not
exclude the impact of systemic consequences of HCV infection,
for example, due to immune dysregulation or systemic inﬂam-
mation, since the latter can reduce myocardial function [4]. This
might indeed be the case in this study, since the severity of
cardiac abnormalities correlated with the histologic activity in
the liver and indocyanine green clearance (a measure of liver
function); thus, more liver injury and dysfunction might lead
to greater systemic inﬂammation that impairs myocardial
function, even in non-cirrhotics, since cirrhotics were excluded
in the Maruyama report. It would have been interesting to
assess markers of systemic inﬂammation, for example C-reactive
protein. This suggestion, however, underscores how primitive
our ability is to rigorously quantify immune function in clinical
practice. Immune dysregulation associated with HCV is widely
recognized [5], but its assessment is not part of the clinical
management of the disease.
Because this report and almost all prior studies describing
HCV effects on heart were performed in Japanese patients, it is
also worth considering whether there are genetic polymorphisms
common to this ethnicity that make cardiac abnormalities more
likely to occur with HCV infection. Of course, the simplest way
to address this possibility is by performing similar studies in
non-Japanese with HCV to assess the prevalence of cardiac
dysfunction.
Finally, are the abnormalities clinically important, since car-
diac dysfunction is not a common clinical problem in HCV-
infected patients? It is possible, as the authors point out, that
HCV or its consequences affect the potassium pump (which is
also required for cellular uptake of thallium), leading to a defect
in potassium homeostasis that impedes endothelial cell function.
Moreover, does HCV-related endothelial cell dysfunction in heart
reﬂect a broader impact of HCV on vascular homeostasis system-
ically? At the very least, evidence of a bona ﬁde impact of chronic
HCV infection on either myocytes or endothelium might help
clarify its impact on other tissues where there is a greater clinical
concern. For example, HCV infection has been linked to neurocog-
nitive deﬁcits [6], and a recent study demonstrated infection of
endothelial cells of the blood–brain barrier [7], focusing attention
on this critical cell type as a mediator of HCV’s effects in other
tissues.
The endothelium is also a focus of the study by Marrone
et al., but in this case the work addresses the biology of the13 vol. 58 j 1–2
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hepatic sinusoidal endothelium. Speciﬁcally, the investigators
build upon an earlier study [8] that demonstrated induction of
the zinc ﬁnger transcription factor, Krüppel-like factor 2
(KLF2), within sinusoidal endothelial cells of cirrhotic liver.
KLF2 is one of a large family of related Krüppel-like transcrip-
tion factors that share the same DNA binding domain but have
divergent amino-terminal activation domains that confer a
broad range of biologic activities [9,10]. The contribution of
KLF2 to vascular endothelial cell homeostasis has been well
established [11,12], and much of the data in the Marrone paper
recapitulates an earlier study in vascular endothelial cells
demonstrating a potent effect of statins in promoting KLF2-
dependent nitric oxide and thrombomodulin induction [13].
Marrone and colleagues similarly demonstrate that several stat-
ins induce KLF2 in cultured sinusoidal endothelial cells, which
leads to up-regulation of endothelial nitric oxide synthase and
thrombomodulin. The effect was blunted by providing mevalo-
nate to overcome the inhibition of HMG-CoA reductase by
statins (their main mechanism of action), and was also inhibited
by using siRNA to KLF2 to reduce its expression. Moreover, this
effect on endothelial cells led to reduced paracrine activation in
culture of a human hepatic stellate cell line (LX-2), as assessed
by expression of alpha smooth muscle actin, consistent with a
recent study that underscores the importance of endothelial
cells in regulating stellate cell activation [14].
The ﬁndings foreshadow interesting newmolecular and trans-
lational directions. From the molecular perspective, a complete
readout of KLF2’s transcriptional targets and the impact of statins
in sinusoidal endothelium could be assessed using a range of
techniques including cDNA array, chromosomal IP-sequencing
(ChIP-seq) or even direct transcriptome or exome deep sequenc-
ing [15,16]. Such unbiased approaches might reveal other cyto-
protective targets downstream of KLF2 that have not previously
been uncovered. In addition, the mechanism linking inhibition
of HMG-CoA reductase (i.e., reduced cholesterol biosynthesis)
to KLF2 induction in this cell type is entirely obscure and merits
further inquiry. From a translational perspective, the ﬁndings
could lead to long-term studies of statin usage, building upon
an earlier report by the same group in cirrhotics [17], to deter-
mine their effect not only on portal hypertension, but also on
ﬁbrosis and vascular remodeling. While unlikely to be sufﬁciently
potent alone to treat ﬁbrosis, statins might provide synergistic
activities when combined with either existing or new antiﬁbrotic
agents. Statins are also likely to have many other cellular and
molecular targets of action in liver besides KLF2, in particular
through down-regulation of inﬂammation [18]. Nonetheless, by
clarifying their mechanisms of action, more potent and selective
inducers of vasoprotection could be discovered, whether or not
they exert their effects through KLF2.
Together, these two studies link liver disease with vascular
biology, and reinforce a connection that is likely to yield further
insights with continued exploration using molecular methods
and in vivo models.2 Journal of Hepatology 2Conﬂict of interest
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